联康生物科技集团年报2024

AGILEAGILE 目錄24712333753737879818284165166 聯康致力透過創新療程改善患者的生活質素 我們對質量的承諾 0690 GMP– ® 主要財務摘要 6365789 1EBITDA (LBITDA) 365 365 83.4%毛利率 9.5%研發費用佔收益的比例 552,980 心創造新醫藥 主席報告 主席報告 主席報告 14.1%82.8®®®20% 1.2.®3.®4. ®Skbrella ™ FN®®63.0 ®®Skbrella ™ FN®® (CDE)® Uni-PTH PTH EGF 促進增長國際視野 管理層討論及分析 管理層討論及分析 4892.7%76.7% 10%10–15% — ®®®®®® ®62.9® 14.1%553.016.8%82.8 0.27720% ® ®®®51388%9%® ®70%750® 管理層討論及分析 ®(FDA)FDA®®® ® ®Skbrella™ FN® 6,000 36042028.4% (BFS)(API) (CDE)BFS 管理層討論及分析 UNI-PTH — Uni-PTH1–34Uni-PTHUni-PTHUni-PTHUni-PTH Uni-PTH®® Uni-PTHUni-PTH — ® BFSEGF UB102 — wAMD™ UB102(wAMD)UB101UB102UB102-AVEGF-A-2(Ang-2) FaricimabAMD(DMO)Ang–2VEGF-AFaricimab34UB102 3.44.8 UB106 — (GBB)TigerMed Pebble Accelerator 管理層討論及分析 25%35%211%— DNA 30–100(MSC) 管理層討論及分析 P2Y2 ®BFS 8%200®IAIM36319%14.7166.56% 553.014.1%® 91.991.9API461.1392.817.4%2.483.4%9.2%9.8%49.8%47.3%47%52.3 82.816.8%1.3521.4% ®®®®®®35.8%7.7%43.4%1.7%11.4%0.003% ® ®®197.96.7%®700%1901,098® ® ®®41.342.52.9%®® 管理層討論及分析 ® ®2.9%247.4240.3 ® ®®10.49.410.2%® ® ®®62.9®®70% ® ®Skbrella ™ FN®®®®® 553.014.1% ®®®®303.433.7%54.9% ®®249.63.2% 461.1392.817.4%81.0%2.483.4% 261.6241.38.4%®49.8%47.3% 52.335.647%Uni-PTH 管理層討論及分析 50.747.47.0%9.2%9.8% 8.913.634.9%CMO 70.982.816.8%® IMARC Group7.5%10%15% ®PTH ®Skbrella ™ FN®®® Tiger Jade Pebble Accelerator ®1.2% 管理層討論及分析 PTHFDA (rhBMPs)® EGF 1,900®®10BFS® EGF 65,009,000104,884,000517,552,000409,992,000318,779,000238,096,000123,496,000114,790,00023.9%28% 管理層討論及分析 15.617.4 4873422315694 0.277 (a) (b) (c) C1 C3 管理層討論及分析 5,800,00016 (i)(ii)Deer Biotherapeutics LimitedDeer Biotherapeutics Limited Deer Biotherapeutics Limited(a)50.5%(b)12.24%(c)8.16%(d)Fengde Healthcare Fund Limited12.24%60%40%(e)Deer Biotherapeutics Limited8.69%(f)Deer Biotherapeutics Limited4.5% 1414A 1214A.810.1%5%14A 8,500,000 Deer Biotherapeutics LimitedDeer BiotherapeuticsLimited Deer Biotherapeutics Limited(a)50.50%(b)12.24%50%(c)8.16%(d)Fengde Healthcare Fund Limited12.24%60%40%(e)Deer Biotherapeutics Limited8.69%(f)8.18% (1)A7,150,0003.65%24(2)B2,350,0003.65%(3)5,800,0003.45%16 (i)(ii)(iii)(iv) 管理層討論及分析 1414A 0.1%5%14A B 75,685.471243 8.198.67B BBBBBGreater Bay Capital LimitedBB B(i)Judy Lau65%(ii)20%(iii)15%BB14A 董事及高級管理層簡介 38(Imperial College London)INSEAD (Capital Magazine)2020 5520 65(University of Hartford)20 Sun New Media Group Limited 董事及高級管理層簡介 6030 20 50(CPA) 20 3730Dana-Farber Cancer Institute/Broad InstituteNGS 5928 70 2710CIGNA CorporationGallup Inc.Carta Group Limited 45(CFA) 18155003788 董事及高級管理層簡介 4318A(600535.SH)MBA 4610CTANDA20 4418 38515 4216 企業管治報告 C1 C1 企業管治報告 ** ABC * 14 企業管治報告 C.2.1 (1)(2) (1)(2)(3) 3.21 ——————————— 企業管治報告 2/22/22/2 ————————17 (i)(ii)(i i i) 17 14 1,000,0001,000,0011,500,0001,500,0012,000,0002,000,0012,500,0002,500,0013,000,0003,000,0013,500,000 企業管治報告 ——————— http://www.uni-bioscience.com 3.13 (1)(2)(3)(4) (1)(2)(3)(4)(5) 企業管治報告 C3 • • •• ••• 企業管治報告 1.6 8110% 10010097100 1.2.3.133.4.5. 企業管治報告 205502 58205502(2) 223 (www.hkex.com.hk)(http://www.uni-bioscience.com) 205502info@uni-bioscience.com 企業管治報告 董事會報告 386 78 0.277 34 8136 (i)(ii) 79B22 董事會報告 42 86(3) 87(1)87(2) 3.13 (1) (2)50,0001215,000,00012 董事會報告 14 39 571352C3XV 董事會報告 1.L2.(i) Automatic Result LimitedAutomatic Result1,650,971,464Automatic ResultMJKPC Holdings LimitedMJKPC Holdings Limited(ii) 26,259,0003.6,420,0004.(i)171,094,438(ii)10,480,0005.(i)8,055,000(ii)85,120,0006.7.8.9.10.(i)130,893,000(ii) 48,000,00011.5,971,228,147 XV 336 1.L2.Automatic Result LimitedMJKPC Holdings LimitedMJKPC Holdings Limited3.Overseas Capital Assets LimitedOverseas Capital Assets LimitedHe Rufeng4.5,971,228,147 336 董事會報告 31.0%37.8%10.7%14.5% 63.7%74.3%16.5%20.9% 5% (i)(ii) 10% 1% 1.00 (i)(ii)(iii) 董事會報告 (i)(ii)(iii)(iv)(v)(vi)(vii)(viii) 28110 193,240,0003.15%193,240,0003.15%121% (1) (2) (i)(ii)(iii)12211101 10%487,651,0128.17%143,142,01293,142,012394,509,0006.42%121% 董事會報告 36 (1)(2)AAA(3)ABCABCABCABCABCABC40,000,000(4)DDD(5)EEEEE(6)0.066 董事會報告 307,540,000 41 董事會報告 16 Top Environmentally Friendly Enterprise 5R —(Reduce)—(Re-evaluate)—(Reuse)—(Recycle)—(Rescue) (a) (b) 5 309028100% (c) 316301202456.2% 董事會報告 獨立核數師報告 78165 獨立核數師報告 2425 54,793,00030,672,00011%6% 7,395,0005,716,000 ———— • ••••• P04659 綜合損益及其他全面收益表 綜合財務狀況表 綜合財務狀況表 綜合權益變動表 綜合現金流量表 綜合財務報表附註 1. 42 2. (a)— 115—77 2. (b) 181910 28 1234 97 97 18 18 綜合財務報表附註 3. (a) (b) 4. (a) (b) 4. (b) 5%6.6%–20%10%–20%5%–18%15%–20% (c) (i)(ii) 4. (c) (i)(ii)(iii)(iv) 4(b) 16 4. (c) (i) (ii) (iii) (d) (e) (i) 10151010 4. (e) (ii) •••••• 4. (f) 15 綜合財務報表附註 4. (f) (g) 20% 4. (h) 15 (i) •• 4. (h) (i) 12 4. (h) (i) ••••• 90 4. (h) (i) 90 •••• 4. (h) (i) • • • • 綜合財務報表附註 4. (h) (i) (ii) (i) 4. (